- $1.98bn
- $1.68bn
- $509.34m
- 55
- 19
- 53
- 38
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 351 | 494 | 535 | 538 | 509 |
Cost of Revenue | |||||
Gross Profit | 263 | 388 | 420 | 423 | 381 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 352 | 464 | 579 | 627 | 742 |
Operating Profit | -0.914 | 30.4 | -44.3 | -89.5 | -233 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -8.82 | 18.1 | -52.1 | -81.8 | -192 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7.23 | 8.54 | -58.4 | -92.5 | -207 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -7.23 | 19.8 | -58.4 | -92.5 | -207 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.23 | 19.8 | -58.4 | -92.5 | -207 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.074 | 0.078 | -0.564 | -0.882 | -1.95 |